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Background: Chronic Obstructive Pulmonary Disease (COPD) is characterized by lung and systemic inflammation as
well as airway goblet cell hyperplasia (GCH). Mucin production is activated in part by stimulation of the epidermal
growth factor (EGF) receptor pathway through neutrophils and macrophages. How circulating cytokine levels relate
to GCH is not clear.
Methods: We performed phlebotomy and bronchoscopy on 25 subjects (six nonsmokers, 11 healthy smokers, and
eight COPD subjects FEV1 30–60 %). Six endobronchial biopsies per subject were performed. GCH was measured by
measuring mucin volume density (MVD) using stereological techniques on periodic acid fast-Schiff stained samples.
We measured the levels of chemokines CXCL8/IL-8, CCL2/MCP-1, CCL7/MCP-3, CCL22/MCD, CCL3/MIP-1α, and
CCL4/MIP-1β, and the cytokines IL-1, IL-4, IL-6, IL-9, IL-17, EGF, and vascular endothelial growth factor (VEGF).
Differences between groups were assessed using one-way ANOVA, t test, or Chi squared test. Post hoc tests after
ANOVA were performed using Bonferroni correction.
Results: MVD was highest in healthy smokers (27.78 ± 10.24 μL/mm2) compared to COPD subjects (16.82 ±
16.29 μL/mm2, p = 0.216) and nonsmokers (3.42 ± 3.07 μL/mm2, p <0.0001). Plasma CXCL8 was highest in healthy
smokers (11.05 ± 8.92 pg/mL) compared to nonsmokers (1.20 ± 21.92 pg/mL, p = 0.047) and COPD subjects (6.01 ±
5.90 pg/mL, p = 0.366). CCL22 and CCL4 followed the same trends. There were no significant differences in the
other cytokines measured. When the subjects were divided into current smokers (healthy smokers and COPD
current smokers) and non/ex-smokers (nonsmokers and COPD ex-smokers), plasma CXCL8, CCL22, CCL4, and MVD
were greater in current smokers. No differences in other cytokines were seen. Plasma CXCL8 moderately correlated
with MVD (r = 0.552, p = 0.003).
Discussion: In this small cohort, circulating levels of the chemokines CXCL8, CCL4, and CCL22, as well as MVD,
attain the highest levels in healthy smokers compared to nonsmokers and COPD subjects. These findings seem to
be driven by current smoking and are independent of airflow obstruction.
Conclusions: These data suggest that smoking upregulates a systemic pattern of neutrophil and macrophage
chemoattractant expression, and this correlates significantly with the development of goblet cell hyperplasia.
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Table 1 Inclusion and exclusion criteria
Inclusion criteria
Age between 40 and 70 years
Diagnosis of COPD or at risk for COPD
Smoking History >10 pack years (for nonsmokers less than 100
cigarettes in lifetime)
FEV1 30–60 % (COPD group), normal FEV1 (Healthy Smoker Group)
English speaking
Exclusion criteria
Diagnosis of chronic sinusitis or allergic rhinitis
Presence of other lung disease (including asthma)
Pregnancy
Sinusitis or URI within the last 6 weeks
COPD Exacerbation within 6 weeks of screening visit
Presence of infiltrate or mass on CT scan
Anticoagulation or antiplatelet therapy within 6 half lives of
bronchoscopy
Known allergy to lidocaine
Predisposition to bleeding
Chronic treatment with steroids, oral or inhaled that cannot be
discontinued for 4 weeks prior to study
Unwillingness to participate in study
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Chronic Obstructive Pulmonary Disease (COPD) is char-
acterized by an abnormal inflammatory response to nox-
ious environmental stimuli in the lung [1]. Persistent lung
inflammation leads to the development of emphysema
and airway disease, of which goblet cell hyperplasia
(GCH) is a crucial component [2]. GCH is a common
phenomenon in COPD, regardless of the presence or ab-
sence of chronic bronchitis (CB) [3–5]. It has been shown
that subjects with more airflow obstruction have a greater
burden of mucus in the small airways [4]. In addition, a
bronchoscopic study in smokers with and without airflow
obstruction demonstrated more GCH in the large airways,
particularly in those with COPD [5]. However, there is a
large disconnect between symptoms of cough and sputum
and mucus burden [6]. The most well characterized
pathologic index described by Reid has shown only a weak
relationship between chronic bronchitic symptoms [7].
While well described in asthma, the inflammatory
mechanisms responsible for GCH in COPD are not well
known. It has been established that subjects with airflow
obstruction demonstrate greater neutrophilic, lympho-
cytic, and macrophage infiltration in the lung parenchyma
which increases as lung function declines [3, 4, 8], but
how trafficking of these cells to the airways occurs is not
known. To complicate matters, it has been increasingly
recognized that COPD is associated with significant
systemic inflammation, but the association between sys-
temic inflammation and lung GCH is not known. We
sought to characterize the systemic cytokine profiles and
relate them to GCH. We hypothesized that elevations in
systemic cytokines would be associated with increased
GCH as a result of immune trafficking to the lung and
subsequent mucin production. Specifically, because neu-
trophils and macrophages are associated with mucin gene
expression [9], we hypothesized that plasma proinflamma-
tory chemokines which mobilize neutrophils and macro-
phages, particularly interleukin-8 (CXCL8), monocyte
chemotactic proteins-1 and −3 (CCL2 and CCL7), macro-
phage derived chemokine (CCL22), and macrophage
inflammatory proteins-1α and -1β (CCL3 and CCL4),
would correlate with GCH in smokers and ex-smokers
with and without COPD.
Methods
This study was approved by the Temple University School
of Medicine IRB (protocol no. 20687). Written informed
consent to participate was obtained by the PI (VK). We
performed phlebotomy and bronchoscopy on 25 subjects
(six nonsmokers, 11 healthy smokers, and eight COPD
subjects). Inclusion and exclusion criteria are summarized
in Table 1. Briefly, for COPD subjects, we included those
with an FEV1 between 30 and 60 %, because this group is
considered at high risk for exacerbation. Healthy smokersneeded to have at least a 10-pack year history of smoking.
Healthy nonsmokers served as a control group. We
excluded those with upper airway disease such as allergic
rhinitis or chronic sinusitis, those with a COPD exacerba-
tion, upper respiratory tract infection, or acute sinusitis
within 6 weeks prior to bronchoscopy in order to exclude
the possible effects of upper airway GCH on lower airway
GCH. We also excluded those with abnormal coagulation
profile or on anticoagulation within 6 half-lives of the
bronchoscopy, and those with a known allergy to lido-
caine. Subjects treated with inhaled corticosteroids had a
washout period of 4 weeks prior to bronchoscopy, to neg-
ate their possible effects on GCH. We excluded those
deemed high risk for discontinuation of inhaled cortico-
steroids (e.g., history of frequent exacerbations).
Six endobronchial biopsies per subject were performed.
After premedication with intravenous fentanyl and mid-
azolam, bronchoscopy was performed using local
anesthesia with topical lidocaine. Endobronchial mucosal
biopsies were performed at carinae of segmental airways,
in the right lower lobe, right middle lobe, and right sec-
ondary carina (branch point between right upper lobe and
bronchus intermedius). Plasma was collected on the same
day as bronchoscopy. Briefly, 20 ml of blood was collected
by venous puncture into vacutainers containing EDTA as
the anticoagulant. The blood was layered on 15 ml of
Ficoll-Paque Plus (GE Healthcare), and centrifuged for
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stored at −80 °C.
GCH was measured by measuring mucin volume dens-
ity (MVD) using stereological techniques on periodic acid
fast-Schiff stained samples. Examples of images from a
healthy nonsmoker and a healthy smoker are shown in
Fig. 1. Mucin volume was measured using a modified
model described by us [10] using Image J. Length of
basement membrane (LBM) and total area of mucin
granules (MA) were measured. MVD (μL/mm2) was
calculated using stereologic techniques as described
previously [11, 12]: MVD =MA/(LBM)(4/π).
Plasma was analyzed for cytokine and chemokine
levels using the Luminex platform. EMD Millipore cyto-
kine kit, HCYTOMAG-60K-29, was purchased and the
following analytes measured: IL-1β, IL-4, IL-6, CXCL8,
IL-9, IL-12p40, IL-15, IL-17, CCL2, CCL7, CCL22,
CCL3, CCL4, Eotaxin, IP-10, interferon-gamma (IFN-γ),
granulocyte colony stimulating factor (G-CSF), epider-
mal growth factor (EGF), IFN-α2, transforming growth
factor-alpha (TGF-α), and vascular endothelial growth
factor (VEGF).
Statistics
Statistical analysis was performed using SPSS v22 (SAS,
Cary, NC) and graphs created with Graphpad Prism v6.03.
Differences between the three groups (nonsmokers,
healthy smokers, COPD) were assessed using one-way
ANOVA or Chi squared test. Post hoc tests after ANOVA
were performed using Bonferroni correction. In addition,
an analysis of all current smokers vs. all non- or ex-
smokers was performed with t test and Chi squared test.
A p value of <0.05 was considered statistically significant.
Correlations between plasma cytokines and MVD were
performed using Spearman’s correlation.Fig. 1 Examples of mucosal biopsies from (a) and (b) healthy nonsmokers,
40×. Specimens stained with periodic acid Schiff-Alcian Blue, staining gobleResults
The clinical and physiologic characteristics, as well as the
MVD, of the subjects are summarized in Table 2. There
was no statistically significant difference in age, gender, or
body mass index between groups. There were more
African-Americans in the COPD group compared to the
healthy smoker and nonsmoker groups. By definition, the
COPD group had worse spirometry compared to the
healthy smoker and nonsmoker group, and smoking his-
tory was not different between the COPD and healthy
smoker groups. Five out of eight (62.5 %) of the COPD
group were current smokers, compared to 100 % in the
healthy smoker group. Five out of eight (62.5 %) in the
COPD group had chronic bronchitis, defined by chronic
cough and sputum at least 3 months a year for at least
two consecutive years. Two out of the 11 healthy smokers
(18.2 %) had chronic bronchitis. To our surprise, the
MVD was greatest in the healthy smoker group (27.78 ±
10.24 μL/mm2) compared to the nonsmoker group (3.42
± 3.07 μL/mm2, p <0.001). In the COPD group, the MVD
was less than the healthy smoker group (16.82 ± 16.29 μL/
mm2), but the difference was not statistically significant
(p = 0.216).
The levels of plasma chemokines and cytokines are
summarized in Table 3. Plasma CXCL8 was greatest in the
healthy smoker group (11.05 ± 8.92 pg/mL) compared to
the nonsmoker group (1.20 ± 21.92 pg/mL, p = 0.047) and
COPD group (6.01 ± 5.90 pg/mL, p = 0.366). See Fig. 2.
Similar trends were seen in CCL22 and CCL4, where con-
centrations of these chemokines were greatest in the
healthy smoker group, and significantly different from the
nonsmoker group but not the COPD group. CCL7 was
greatest in the COPD group (50.74 ± 25.88 pg/mL)
compared to the nonsmoker group (17.33 ± 14.44 pg/mL,
p = 0.028) and the healthy smoker group (40.66 ±(c) and (d) healthy smokers,and (e) and (f) COPD subjects, taken at
t cells blue/purple
Table 2 Demographic factors, BAL results, mucin volume density
Nonsmokers Healthy smokers COPD
n = 6 n = 11 n = 8 p
Age (years) 47.60 ± 11.82 49.58 ± 5.57 57.0 ± 4.66 0.052
Gender (male, n (%)) 4 (66.7) 4 (36.3) 5 (62.5) 0.327
BMI (kg/m2) 31.13 ± 5.26 30.78 ± 4.74 29.30 ± 5.88 0.743
Racea (White, n (%)) 3 (50.0) 2 (18.2) 0 (0) 0.035
FEV1 ( % pred) 89.50 ± 20.52* 101.17 ± 16.30* 46.25 ± 8.83 <0.0001
FVC ( % pred) 92.90 ± 16.23 103.67 ± 16.87* 74.13 ± 12.70 0.001
FEV1/FVC 88.2 ± 21.70* 96.67 ± 6.14* 52.38 ± 11.95 <0.0001
Smoking History (pack years) 0* ** 25.58 ± 10.66 22.25 ± 9.00 <0.0001
Current Smoking (n, %) 0 (0) 11 (100) 5 (62.5) <0.0001
Chronic Bronchitis (n, %) 0 (0) 2 (18.2) 5 (62.5) 0.006
MVD (μL/mm2) 3.42 ± 3.07** 27.78 ± 10.24 16.82 ± 16.29 0.002
aOther race is Black. *p <0.05 compared to COPD, **p <0.05 compared to Healthy Smokers
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ences between groups in CCL2, CCL3, or other cytokines.
Subjects were subsequently divided into current
smokers (including healthy smokers and COPD subjects)
and non- or ex-smokers (nonsmoker group plus COPD
subjects that quit smoking). As there were only threeTable 3 Plasma chemokines
Nonsmokers (n = 6)
Chemokines Eotaxin 83.92 ± 57.41
CXCL8 1.20 ± 21.92*
IP10 233.94 ± 125.07
CCL2 200.98 ± 128.03
CCL7 17.33 ± 17.44**
CCL22 714.23 ± 524.71*
CCL3 17.44 ± 25.47
CCL4 9.69 ± 10.50*
Th1 IFNγ 4.21 ± 2.63
IL12p40 Undetectable
Th2 IL4 10.71 ± 13.20
IL9 1.16 ± 1.83
Th17 GCSF 83.92 ± 57.41
IL6 11.39 ± 2.58
IL17 Undetectable
Other EGF 12.65 ± 3.31
IFNα2 17.19 ± 11.28
IL1β 2.86 ± 4.44
IL10 9.35 ± 7.73
IL15 5.18 ± 3.52
TGFα Undetectable
VEGF 130.03 ± 100.23
*p <0.05 vs. healthy smokers, **p <0.05 vs. COPDformer smokers in the analysis, they were grouped to-
gether with the non-smokers. Plasma cytokine levels
were compared between these two groups. The results
are summarized in Table 4. The concentration of plasma
CXCL8 was greater in the current smoker group com-
pared to the non- or ex-smokers. Plasma CCL22 andHealthy smokers (n = 11) COPD (n = 8) P
96.16 ± 58.86 96.42 ± 75.40 0.920
11.05 ± 8.92 6.01 ± 5.90 0.028
671.55 ± 544.81 670.36 ± 751.53 0.287
310.63 ± 149.19 207.02 ± 76.06 0.106
40.66 ± 22.34 50.74 ± 25.88 0.031
1335.51 ± 486.74** 750.37 ± 251.39 0.009
7.88 ± 21.72 8.33 ± 3.55 0.255
42.04 ± 24.48 25.98 ± 15.60 0.009
9.58 ± 6.13 19.24 ± 28.76 0.253
38.97 ± 8.01** 20.44 ± 17.22 0.035
15.35 ± 12.26 47.77 ± 81.07 0.256
1.71 ± 1.44 2.66 ± 2.95 0.389
74.14 ± 81.80 25.79 ± 25.96 0.059
9.46 ± 2.46 64.27 ± 163.01 0.410
8.76 ± 0.87 8.62 ± 1.03 0.809
13.96 ± 8.19 19.16 ± 19.66 0.559
57.43 ± 37.42 67.87 ± 71.16 0.155
1.97 ± 2.59 5.30 ± 7.01 0.323
6.78 ± 6.08 16.11 ± 27.39 0.478
5.53 ± 3.20 5.75 ± 5.19 0.965
Undetectable Undetectable
195.44 ± 55.90 258.95 ± 295.52 0.427
Fig. 2 Plasma cytokines a) CXCL8, b) CCL4, c) CCL22 and d) MVD by group. *p <0.05 compared to healthy smokers
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There were no significant differences in CCL2, CCL3,
CCL7, or other cytokines between these groups. MVD
was greater in the current smokers compared to the
nonsmokers. See Fig. 3. Finally, there was a moderate
correlation between plasma CXCL8 and MVD (r = 0.552,
p = 0.003). See Fig. 4. There were no significant correla-
tions with other plasma chemokines.
Discussion
As previously shown, we found that GCH was greatest
in smokers without airflow obstruction compared to
COPD subjects and nonsmokers, and that this effect was
primarily driven by current smoking [13]. In this small
cohort, we demonstrated that plasma chemokines
CXCL8, CCL22, and CCL4 were also greatest in the
healthy smoker group, following the same pattern as the
degree of GCH. These cytokines were also greater in
those currently smoking, suggesting a causal relationship
between smoking and these cytokines which result in
GCH. Interestingly, we found that CCL7 was greatest in
the COPD group, but found no other significant differ-
ences in other cytokines between groups. Finally, we
showed that there was a moderate correlation with
plasma CXCL8 concentrations with MVD. These find-
ings suggest that smoking upregulates these plasma neu-
trophil and macrophage chemokines which result in the
development of lung GCH.
Several cytokines and biomarkers have been examined
in COPD subjects in various compartments, includingplasma, sputum, and BAL. The most well characterized
ones include C-reactive protein, fibrinogen, surfactant
protein-D, IL-6, TNF-α, and CXCL8 [14–17]. However,
prior literature has emphasized levels in COPD subjects
in the chronic stable state compared to controls, com-
pared to periods of exacerbation, or in response to ther-
apy [14, 15, 17–19]. Hurst et al. found that systemic
levels of IL-6 correlated with sputum concentrations of
CXCL8 during exacerbations compared to the chronic
stable state [15]. Sin et al. reported that inhaled fluticasone
and fluticasone/salmeterol combination reduced systemic
levels of surfactant protein-D but not C-reactive protein
or IL-6 [19]. Few studies have addressed the role of
cytokines in relationship to GCH in smokers with and
without airflow obstruction. Interestingly, we found that
the levels of certain chemokines, particularly CXCL8, were
significantly correlated with GCH. Another interesting
finding was that smokers without airflow obstruction had
greater MVD compared to COPD subjects, a novel finding
compared to prior studies [4, 5].
CXCL8 has been the subject of many prior investiga-
tions in COPD. CXCL8 is a potent neutrophil chemo-
attractant [20], which is a known stimulant of mucin
production and degranulation of mucin stores [21].
CXCL8 also regulates mucin gene expression at the post-
transcriptional level [22]. A bronchoscopic study of 39
COPD subjects and 18 healthy controls found that CXCL8
in BAL was significantly higher in frequent exacerbators
[23]. Furthermore, recent studies have shown that CXCL8
levels are significantly elevated in the blood in COPD
Table 4 Plasma chemokines and mucus volume density in current smokers vs. non- or ex-smokers
Non- or ex-smokers (n = 9) Current smokers (n = 16) p
Chemokines Eotaxin 88.87±84.90 95.87±51.47 0.791
CXCL8 2.11±3.98 9.43±7.94 0.016
IP10 295.19±157.43 713.20±676.25 0.082
CCL2 213.03±113.31 265.32±135.19 0.329
CCL7 36.33±34.82 40.65±20.23 0.686
CCL22 653.56±439.54 1239.50±498.06 0.006
CCL3 14.95±20.70 7.78±1.83 0.149
CCL4 14.99±16.20 35.86±21.99 0.019
Th1 IFNγ 18.17±31.31 8.86±5.15 0.222
IL12p40 30.15a 34.76±15.35 0.778
Th2 IL4 46.94±86.59 16.02±13.72 0.144
IL9 2.43±3.42 1.70±1.30 0.426
Th17 GCSF 12.95±25.71 56.46±68.36 0.079
IL6 71.61±171.16 9.48±3.39 0.129
IL17 9.30a 8.64±0.93 0.510
Other EGF 18.43±19.35 14.18±8.77 0.434
IFNα2 46.90±77.84 55.08±35.52 0.708
IL1β 5.47±7.02 2.37±3.57 0.137
IL10 19.90±28.45 6.47±5.15 0.059
IL15 6.89±5.07 4.86±3.23 0.217
TGFα Undetectable Undetectable
VEGF 156.87±93.82 228.21±221.00 0.366
MVD 7.41±7.56 24.07±13.70 <0.0001
Plasma chemokines expressed as pg/mL. MVD expressed as μL/mm2
aOnly one sample with detectable levels
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ate with mortality, exacerbation rate, and BODE scores,
and inversely correlate with FEV1 and DLCO [24–26].
Moreover, analysis of the levels of CXCL8 in BAL and
sputum found higher levels of sputum CXCL8 in COPD
subjects compared to healthy smokers and nonsmoking
controls but no difference in BAL CXCL8 [27]. However,
one study found BAL CXCL8 levels to be greater in
smokers and COPD subjects compared to normal controls
[28], and another study showed that BAL CXCL8 levels
could distinguish current smokers with emphysema from
those without emphysema [29]. In contradistinction to
prior studies, we found that plasma CXCL8 levels to be
highest in the healthy smoker group and was highly
dependent on current smoking. Moreover, We found a
moderate correlation between plasma CXCL8 and MVD,
a novel finding in comparison with current literature, and
as the greatest levels of each were found in current
smokers, this association suggests a relationship with
plasma neutrophils and the development of GCH in the
lung. It is known that cigarette smoke causes influx of
neutrophils and macrophages to the lung. Cigarette smokeextract has been shown to increase CXCL8 release from
bronchial epithelial cells in a concentration- and time-
dependent manner [30]. Cigarette smoking acutely in-
creases plasma neutrophil activation as well in young
smokers susceptible to the development of COPD (de-
fined as those with familial aggregation) [31]. Our findings
support this phenomenon by demonstrating the upregula-
tion of the plasma levels of the chemokines CXCL8,
CCL4, and CCL22 in current smokers.
Some studies have tried to relate cytokines with the
presence of chronic bronchitis. A bronchoscopic study
of 42 subjects with chronic bronchitis (with and without
airflow obstruction) and 13 healthy controls found in-
creased activity of CXCL8, myeloperoxidase, hyaluronan,
and eosinophil cationic protein [32]. Sputum CCL2
levels have recently been shown to be increased in
COPD subjects with chronic bronchitis compared to
COPD subjects without chronic bronchitis [33]. In this
study, sputum neutrophil and eosinophil counts were
also higher in the chronic bronchitic group. Moreover,
Monzon et al. described a CCL2/CCR2B dependent loop
which appeared to upregulate mucin gene expression in
Fig. 3 Plasma Cytokines a) CXCL8, b) CCL4, c) CCL22, and d) MVD by current smoking. NS Non- or ex-smokers, CS Current smokers. *p <0.05
compared to current smokers
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Moraes et al. found an association with serum IL-6
levels in ex-smoker COPD subjects with chronic bron-
chitis, but were unable to demonstrate a relationship of
IL-6 or CXCL8 with disease severity [35].
There is growing evidence that CCL22 may be involved
in the pathogenesis of chronic lung inflammation. CCL22
is produced predominantly by monocytes, macrophages,Fig. 4 Relationship between mucus volume density and plasma CXCL8 conand dendritic cells, and is a potent chemoattractant for
macrophages, NK cells, and some T cells [36]. It is appar-
ent that the levels of CCL22 mRNA and protein are
elevated in both lung tissue and lavage fluid in COPD
[37]. The levels of CCL22 are also elevated in the lavage
fluid obtained from patients with idiopathic pulmonary fi-
brosis [38]. Furthermore, Frankenberger et al. recently re-
ported a 10-fold increase in the expression of CCL22 bycentrations
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or smokers [39]. Finally, Belperio et al. have shown that
the levels of CCL22 are overexpressed in a bleomycin
model of murine pulmonary fibrosis [40]. Similarly, the
levels of this chemokine are significantly increased in the
lungs in studies of a rat model of radiation pneumonitis-
related pulmonary fibrosis [41].
Recent reports using experimental animal models have
suggested that CCL4 may play an important role in the
induction of lung inflammation following exposure to
tobacco smoke. Ma et al. report in increase in produc-
tion of CCL4 in the lungs of mice subjected to daily ad-
ministration of cigarette smoke [42]. The receptor for
this chemokine is CCR5, and the administration of to-
bacco smoke to CCR5-deficient mice shows substantially
attenuated lung inflammation when compared to mice
which express normal levels of CCR5 [42, 43]. These re-
sults suggest that the CCL4-CCR5 response loop may
make a substantial contribution to the development of
lung inflammation associated with smoke exposure.
However, it should be pointed out that Meuronen et al.
have reported that CCL4 levels are significantly de-
creased in the BAL of asymptomatic long-term smokers
[44]. This report is in contrast to the results reported
herein, or with the results of studies with chronic bron-
chitis patients in which the levels of CCL4 were found
to be increased in lavage fluid [45]. An explanation for
the disagreement in the results from these studies is not
clear at this time. Less is known about CCL7 in COPD,
but it has been described in other inflammatory diseases
including asthma, multiple sclerosis, and rheumatoid
arthritis [46]. We found that CCL7 plasma levels were
greatest in the COPD group. Further study in a larger
cohort is needed to validate these findings.
In the present study, some cytokines, and GCH, are
downregulated in COPD patients compared to healthy
smokers. Other studies have found that proinflammatory
cytokines and GCH are upregulated in COPD [4, 5, 14].
Corticosteroids were withheld for four weeks prior to
phlebotomy and bronchoscopy, so it is doubtful that the
prior use of inhaled corticosteroids is responsible. We
suggest that current smoking has a more powerful influ-
ence on circulating cytokine levels in this cohort.
This study has several limitations. Firstly, the sample
size is small, meaning studies of greater magnitude are
needed in order to confirm these findings. The biopsies
are of the large airways, which may not represent disease
of the smaller airways where airflow obstruction is
thought to occur. Sampling error of the mucosa is a po-
tential issue, but the biopsies were performed in system-
atic fashion and therefore less likely to be the cause of
the findings. There were significant differences in racial
distribution between the 3 groups, which may have had
bearing on the results. By design, the study recruitedthose with moderate to severe COPD, so little can be
said about those with milder disease. Finally, our data
suggest that plasma levels of four chemokines statisti-
cally correlate with COPD, and three of these (CXCL8,
CCL4 and CCL22) also correlate with mucous volume
density. Nevertheless, at this point little can be said
about immune trafficking of inflammatory cells into the
lung, as plasma cytokine levels and GCH were measured
separately and are purely associations at this point.
Additional studies will be necessary to more fully assess
the contribution of chemokine-driven inflammatory cell
recruitment to the degree of lung disease, particularly
mucous production, in COPD.Conclusions
We found greater degrees of GCH in the healthy smok-
ing group and all current smokers, which correlated with
differences in plasma CXCL8, CCL22, and CCL4 be-
tween groups in similar fashions. These associations
suggest that smoking has a systemic effect on circulating
cytokine levels that lead to the development of GCH.
Further study is needed to corroborate these findings in
a larger cohort.
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